RED BANK, N.J., Nov. 9, 2021 /PRNewswire/ -- Provention Bio,
Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to
intercepting and preventing immune-mediated disease, today
announced it's putting type 1 diabetes (T1D) to the test during
Diabetes Awareness Month this November. The company is calling on
the T1D community to take the #Type1TestedPledge to spread
awareness about risk factors and the importance of screening people
with a family history of T1D for early-stage, pre-symptomatic
disease. Screening may reduce the risk of serious complications and
life-threatening events such as diabetic ketoacidosis. It can also
allow time to prepare for the onset of clinical disease and a
lifetime of insulin administration and glucose monitoring.
T1D is an autoimmune disease affecting 1.6 million Americans and
another 300,000-400,000 Americans have early-stage disease, which
may have no symptoms and go unnoticed while the insulin-producing
cells are progressively destroyed. Family history puts people at up
to 15 times greater risk of developing T1D. The disease can be
detected in the earliest stages - before symptoms occur - through a
blood test for certain autoantibodies. Data show 75% of people with
these autoantibodies will go on to develop clinical, or
insulin-dependent, T1D within five years, and their lifetime risk
is almost 100%.
"The #Type1TestedPledge is deeply rooted in Provention Bio's
mission to seek out and target autoimmunity early. It builds on our
successful 'Type 1 Tested' campaign and national effort to redefine
patient care in T1D," said Jason
Hoitt, Chief Commercial Officer, Provention Bio.
The campaign will be featured on Type 1 Tested and other social
media and digital channels, with support from leading patient
advocacy organizations. People can get involved with the campaign
by pledging to:
- Learn more about the Type 1 Test
- Start a conversation about T1D risk and early screening
- Get Type 1 Tested if you have a family history of T1D
- Connect with the T1D community
Go to www.type1tested.com to learn more about the
#Type1TestedPledge campaign and join the Type 1 Tested community on
Instagram and Facebook.
About Provention Bio, Inc.
Provention Bio, Inc.
(Nasdaq: PRVB) is a biopharmaceutical company focused on advancing
the development of investigational therapies that may intercept and
prevent debilitating and life-threatening immune-mediated disease.
The Company's pipeline includes clinical-stage product candidates
that have demonstrated in pre-clinical or clinical studies
proof-of-mechanism and/or proof-of-concept in autoimmune diseases,
including type 1 diabetes, celiac disease, and lupus. Visit
www.ProventionBio.com for more information and follow us on
Twitter: @ProventionBio.
Internet Posting of Information
Provention Bio, Inc.
uses its website, www.proventionbio.com, as a means of
disclosing material nonpublic information and for complying with
its disclosure obligations under Regulation F.D. Such disclosures
will be included on the Company's website in the "News" section.
Accordingly, investors should monitor this portion of the Company's
website, in addition to following its press
releases, SEC filings and public conference calls and
webcasts.
Investor Contacts:
Robert
Doody, VP of Investor Relations
rdoody@proventionbio.com
484-639-7235
Sam Martin, Argot Partners
sam@argotpartners.com
212-600-1902
Media Contact:
Lori
Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/provention-bio-puts-type-1-diabetes-to-the-test-with-pledge-campaign-for-diabetes-awareness-month-301419109.html
SOURCE Provention Bio, Inc.